New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Sex Workers, MSM, and Transgender Persons: Disruption in access to PrEP services, reduced capacity for HIV prevention services, , reduced availability of HIV counselling and testing, and disruption in ...

Unlike President Trump's picks to lead other health agencies who established their conservative bona fides during the ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...

Kevin Lambert’s satire of a TV presenter’s downfall, May Our Joy Endure, may have won the Prix Médicis – but this translation needed work ...

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...